Glucagon-like peptide-1 drugs and major limb problems in adults with type 2 diabetes and artery disease

Declarations. Ethics approval and consent to participate: Not applicable. This study is a meta-analysis and did not involve direct recruitment of human participants. Generative AI and AI-assisted technologies in the writing process: The authors didn’t use ChatGPT for assistance in the preparation of the manuscript. Competing interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Dario Giugliano reported receiving consultancy fee from Eli Lilly, Sanofi, Novartis, Astrazeneca, and Novo Nordisk; Maria Ida Maiorino reported receiving personal fees from Novo Nordisk, Eli Lilly, and Sanofi; Katherine Esposito reported receiving consultancy fees from Eli Lilly and giving lectures for Eli Lilly, Sanofi, Novo Nordisk, Roche, Bayer, and Lifescan. All other authors declare that they have no competing interests.